Seems to have replaced the former NexGen Investor letter… has a longer holding period than the short-term focused NexGen Trader now called Moneyline? This site uses Akismet to reduce spam.
Learn how your comment data is processed. I subscribed to NextGen Investor back in July of I found the idea of investing in new trends and technology interesting so I subscribed for 2 years at the very good rate.
At first there were not that many stock picks but since it was a new service I figured it would get more interesting with time. Luckily there have been many winning trades. I only sold 1 stock at a slight loss.
For instance, had us buy a position in a NextGen real estate stock. Karen Click on Articles, there you will see all of them. Do you mind sharing the other services that you use besides Matt? For instance, I will have a stock that is supposed to go up on May 31st.
Matt McCall’s Investment Opportunities
I will post it here on May 30th or the morning of May 31st. You never answered me. So here is your chance: geraldbenard ymail. And where is my free report I never got.
Thank you Matt. The only problem is there is an investment involved. I expected some sort of information by now. Am I rushing things, expecting too much too soon, or have I been lost in the the world of high finance?
Check Out My MoneyLine Podcast!
To this date I have not received anything from this group. How do I contact someone to help me become recognized? Has everyone received their package and finding the resources helpful? Recommend you use the Search field here on Stock Gumshoe. As you mention, he is touting it again, I also received a teaser this morning.
There is a great deal about everything that is going on is stocks and Marijuana Stocks. I will know tomorrow two 2 stocks that will do something this week. I thought there would be more than that. Your clarification would be highly appriciated. BR, Hithig.
I think Matt just teases stocks and asks for more money with every newsletter.
I told them so they blocked me from their website. Matt recommended Cansortium, Inc. CNTMFsaying it was a great pot stock to buy, for all the right reasons.
Unless I missed something, Matt never said that the stock was experiencing any problems. I guess he was too busy, trying to sell newsletters. Considering the amount of bravado he exudes on Twitter I expected some stellar returns in his investment letter. To put it succinctly woof as one of my friends would say.Early Stage Investor Research is a Premium-priced monthly newsletter that seeks to recommend small or early-stage investments. Early Stage Investor is geared for investors who are looking to make massive gains from the best early-stage companies that will change the world.
When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small company that grows large. Why the virus has shined a spotlight on 5G in Washington and is helping push the 5G rollout into a whole new growth phase. Register here for FREE. It only takes one of these big hits to make a huge amount of money in early-stage companies.
Venture capitalists are the early backers of start-up companies. They are the grand slam, home run hitters of the investment world. Venture capitalists have funded nearly every mega-hit technology company you know today: Google now AlphabetFacebook, Twitter, Uber, Airbnb, Pinterest, and the list goes on and on. Before the public learned about these innovative businesses, venture capitalists were there, performing due diligence and making early investments. We are looking to hit grand slam home runs.
Early-stage stocks are among the riskiest securities in the market. They are more volatile and have higher failure rates than established businesses like Walmart and Coca-Cola. You hold them for a year. The returns of these 12 stocks are listed below:. In this example, four went up and eight went down. Soros is a genius at knowing how government actions affect markets. Soros once summed it up like this:. He focused on making his successes big and meaningful… and making sure his mistakes were small and manageable.
I get how people feel the need to be right.All rights reserved. As we continue to count down the days until the ball drops, McCall is ready with his new list of predictions.
But, it will also have some success stories. Forhe predicts that Airbnb will be the new IPO stock to avoid, thanks to its crazy high valuation and bad customer service. Make sure to watch it once it prepares to hit the markets. Why does McCall think a mattress company will do so well? But what about the upcoming presidential election? It would be hard to make a list of predictions without weighing in on that.
Many investors fear what would happen in the markets following the election of Massachusetts Sen. Elizabeth Warren.
Those are three big sectors, meaning the stakes are high. Because of these fears, McCall believes that voters will come to the polls to re-elect Trump, regardless of other issues. He believes that a show-stopping name will be added to the collection of Warren Buffett stocks. Could it be a tech company? Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities.
Premium Services Newsletters. Sign out. About Us Our Analysts. Source: InvestorPlace.So all of that, and most of the big picture stuff he cites in the ad, is about the promise of gene editing and genetic therapies in general … and mostly about the rapid speed of advancement in that field thanks to the precise tool that CRISPR-Cas9 editing gives researchers.
Who pays? There was an interesting Wired article on this following the JP Morgan Healthcare Conference a couple months ago, should you want to dig deeper. Our top pick in this sector already has two gene-editing products on the market, two more nearing commercialization, and four more programs in clinics—giving it one of the greatest pipelines of DNA cures in the industry.
They reported their fourth quarter earnings about three weeks ago, you can see some summary notes on that from the Motley Fool here. The company is using combinations of gene therapy, gene editing and immunotherapy to develop treatments for cancers and rare diseases, including ALD and sickle cell disease, but probably their most-followed drug is bb, which is partnered with Celgene for multiple myeloma.
Will bluebird be a huge winner from here? Which indicates to me that he has probably included a bunch of short-term windfall gains, like successful options trades, or perhaps some cryptocurrency trades that had remarkable jumps he did tease some crypto-related stocks for one of his other NexGen newsletters back in December. This site uses Akismet to reduce spam. Learn how your comment data is processed. The druggies will fight this tooth and nail.
If it becomes possible to cut out bad DNA, which I seriously doubt, then drugs will become extinct. Big Pharma wants to keep us sick for decades so that instead of curing us, they can medicate us to death, slowly. It has never come close to happening and never will until perhaps the Dow trades ator some such. Messing with DNA will not cure all diseases. No matter how sophisticated DNA manipulation becomes, drugs will be with us for a long time.
And no, the pharma companies are not trying to keep us sick. There is a lot of work going on to build a better CRISPR enzyme and if this new enzyme is better and patented it could take over rapidly. Recently a long time promoter that works for a company on the Vancouver exchange where I have lost thousands in prior years finally hit it big. Over years he kept promoting a nickel stock when it was at 3 — 5 cents per share and as of last September it went to 11 cents per share.
Travis, as a beginning investor who is only trying to keep my head above water with astronic medical bills due to an unseen spinal cord injury you have no idea how much I appreciate your common sense no nonsense straight to the analytical point. Mike, that is the nicest, most eloquently stated, true comment in existence, regarding Travis, Please except my small gift of one year Irregular membership to StockGumshoe; the only subscription an investor needs for a fighting chance against these effed up markets full of wolves and scammers.Most families have annual traditions as each year comes to a close.
They travel miles and hours to spend time together. They wear matching pajamas and pose in front of Christmas trees. They cook massive turkeys, light candles, and drink far too much eggnog.
I often poke fun at people who participate in the annual crapshoot of wild guesses. That being said, I usually still end up throwing my own best guesses into the ring. They all point me to what I truly believe will come to fruition. To give you an idea of what my predictions are all about — and also to keep myself accountable — let me first provide a quick review of the 10 predictions I laid out for before sharing what I expect for On December 26,I shared my top 10 predictions for The index hit an all-time high of 3, What made this prediction even more impressive was the fact that in Decemberthe market was on the cusp of a recession.
To say that my view was in the minority is an understatement. Both ride-sharing companies did go public. And right on cue, they both disappointed. Each stock has lost at least one-third of its value from its post-IPO high. Fake will be good news. Cryptocurrencies will bounce back. Some of the smaller altcoins are up much more.
Microsoft and its peers struggled throughout much of the year… but the stock joined the trillion-dollar club in mid Oat milk will become the new almond milk.
This started out as a silly, fun prediction, but it came true!
Oat milk is now available at most coffee shops and in the milk aisle at your local grocery store. Now I need to figure out what kind of milk will be hot in …. I stand by each of the four remaining predictions heading in As telehealth continues its way toward the mainstream, I expect some big offers will come in for the company. Amazon is already making waves in the healthcare space, and I see the future acquisition as a smart move.
Amazon will buy a big box retailer. The company purchased Whole Foods Market a couple years ago, and I still believe another big name will be picked up by the grocer. Apple AAPL will finally spend its cash. A large country will be hit with a major cyberattack.All rights reserved.
Until now, there have really only been two ways to get rich investing in marijuana…. After landing several key deals, it quickly became the largest pot company in the world. Today, Canopy Growth Corp. The other way is to start your own cannabis company.
Like Nancy W. The good news is, something remarkable has just happened…. A third type of investment has just opened up in the red-hot marijuana markets…. Premium Services Newsletters. Sign out. About Us Our Analysts. The good news is, something remarkable has just happened… A third type of investment has just opened up in the red-hot marijuana markets…. Sometimes the best way to invest in a high-growth industry trend is not to invest in the trend at all The boom in the marijuana industry will be too big to ignore.
Whether you're a risk-taker or risk-averse, there are multiple ways to buy weed stocks without sitting on the sidelines. There is too much money in the marijuana industry for nations to sit back and watch their peers and enemies profit.
The same can be said of investors who watch from the sidelines as their peers get rich from legal weed. If you miss out on it, you could regret it for the rest of your life. Subscriber Sign in. Sign in. Having trouble logging in?My colleague Louis Navellier and I just released our thoughts on and what you need to do to set yourself up for what we anticipate will be a gangbusters year for stocks.
Louis and I handpicked nine companies we believe will be the biggest winners of Our research and analysis have identified another stock with big potential in When we saw it, we absolutely had to add it to our list and let everyone know right away.Matt’s 2020 Predictions: IPOs, Buffet, Biotech, and More
Many stocks in the biotech sector have begun to thrive after four years of mostly sideways movement. Politics and calls for Medicare for All, as well as plans to drastically scale back drug prices, were a downer for the industry. But notice that in October, the biotech ETF starting to take off again. Industry heavyweights have been on a buying spree, grabbing smaller firms that specialize in treatments for cancer and autoimmune disorders.
Which brings me back to our latest recommendation …. The company already has a massive blockbuster drug under its belt.
The drug has already cornered significant market share and keeps expanding. The firm is partnering with an industry behemoth on another drug and is looking to add an indication — approval for another reason to use the drug — after successful Phase 3 trials.
When it comes to the bottom line, the biotech is on solid footing. Best of all, the stock is relatively cheap when you consider its bottom-line growth potential over the next five years.
You can read more about it by clicking here. We call them our Power Portfolio. Basically, only one out of stocks meet BOTH of our strict requirements. This week, Matt takes a look back at his 10 predictions for and grades each one — more than half were correct! You can subscribe to this podcast on iTunes, Stitcher, Spotify, or wherever you listen to podcasts. The car as we know it is on the verge of a transformative change not seen since Karl Benz invented it nearly years ago.
In fact, the whole transportation sector is now poised for its version of 2.